Fireside Chat with EIR Marc Appel – Biotech in China

​Marc Appel is the founder and Managing Partner of Pacific Bridge NY. He also serves as the leading healthcare advisor to a large US family office. Previously, he founded the drug investment and development platform Orange Grove Bio and served as its CEO where he helped launch and lead multiple portfolio companies, including IpiNovyx Bio, Asalyxa Bio, and Allonix Therapeutics.

​Before founding Pacific Bridge NY and Orange Grove Bio, Marc was a healthcare investor at Marathon Asset Management, where he invested across the capital structure and helped develop a structured healthcare and royalty investing strategy. He began his career at McKinsey & Company.

​Marc  has also served as an advisor to university innovation programs, including the Frankel Fund at the University of Michigan, Yale’s Blavatnik Program, Cornell University’s tech transfer office, and the Dartmouth Innovations Accelerator for Cancer. He frequently speaks at industry conferences and academic institutions and is the co-author of a Harvard Business School case on Imprimis Pharmaceuticals.

​Throughout his career, Marc has founded and invested in many biotech companies and negotiated, structured, and led numerous partnerships with large pharmaceutical companies and has served on the boards of biotechs across stages, therapeutic areas, and modalities.

​He holds a B.A. from Yale University, a J.D. from Harvard Law School, and an M.B.A. from Harvard Business School. He is a member of the New York Bar.

​Marc will address current trends in the China biotech ecosystem: How did China get to where it is today and what do we think the future state looks like? What does this mean for the U.S. biotech industry? How can smaller U.S. startups take advantage of this major paradigm shift?